Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study

Results of a study investigateing polatuzumab vedotin combined with bendamustine and rituximab for treatment of relapsed follicular lymphoma.